Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F-652 in moderate to severe COVID-19
NCT04498377Phase 2Terminated
- Sponsor
- Evive Biotech
- Start
- Jan 2021
- Primary completion
- Mar 2021
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of eflepedocokin alfa in coronavirus disease 2019 (COVID-19), sponsored by Evive Biotech. Started Jan 2021; status: terminated.
02
Drugs
eflepedocokin alfa
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04498377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04498377.